Patent Review (2017-2020) of the Keap1/Nrf2 Pathway Using PatSeer Pro: Focus on Autoimmune Diseases.

Details

Ressource 1Download: antioxidants-09-01138.pdf (2338.21 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Secondary document(s)
Download: Table S1 patents.xlsx (1311.88 [Ko])
State: Public
Version: Supplementary document
License: Not specified
Download: Table S2 keywords.xlsx (21.92 [Ko])
State: Public
Version: Supplementary document
License: Not specified
Download: Table S3 topics.xlsx (25.63 [Ko])
State: Public
Version: Supplementary document
License: Not specified
Serval ID
serval:BIB_E93BD1550E44
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Patent Review (2017-2020) of the Keap1/Nrf2 Pathway Using PatSeer Pro: Focus on Autoimmune Diseases.
Journal
Antioxidants
Author(s)
Chartoumpekis D.V., Fu C.Y., Ziros P.G., Sykiotis G.P.
ISSN
2076-3921 (Print)
ISSN-L
2076-3921
Publication state
Published
Issued date
17/11/2020
Peer-reviewed
Oui
Volume
9
Number
11
Pages
E1138
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Abstract
Research on the antioxidant pathway comprising the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) and its cytoplasmic inhibitor Kelch-like ECH-associated protein 1 (Keap1) is ever increasing. As modulators of this pathway have started to be used in clinical trials and clinical practice, Nrf2 has become the subject of several patents. To assess the patent landscape of the last three years on Nrf2 and evaluate the main fields they refer to, we used the web-based tool PatSeer Pro to identify patents mentioning the Nrf2 pathway between January 2017 and May 2020. This search resulted in 509 unique patents that focus on topics such as autoimmune, neurodegenerative, liver, kidney, and lung diseases and refer to modulators (mainly activators) of the Nrf2 pathway as potential treatments. Autoimmunity emerged as the main theme among the topics of Nrf2 patents, including a broad range of diseases, such as systemic sclerosis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel diseases, Hashimoto's thyroiditis, etc.; however, there was a dearth of experimental support for the respective patents' claims. Given that chronic inflammation is the main element of the pathophysiology of most autoimmune diseases, the majority of patents referring to activation of Nrf2 as a method to treat autoimmune diseases base their claims on the well-established anti-inflammatory role of Nrf2. In conclusion, there is strong interest in securing intellectual property rights relating to the potential use of Nrf2 pathway activators in a variety of diseases, and this trend parallels the rise in related research publications. However, in the case of autoimmunity, more research is warranted to support the potential beneficial effects of Nrf2 modulation in each disease.
Keywords
autoimmunity, nuclear factor erythroid 2-like factor 2 (Nfe2l2), oxidative stress, patent landscape, text mining
Pubmed
Web of science
Open Access
Yes
Funding(s)
Swiss National Science Foundation / Projects / 31003A_153062
Swiss National Science Foundation / Projects / 31003A_182105
Swiss National Science Foundation / Projects / IZCOZ0_177070
Swiss National Science Foundation / Projects / IZSEZ0_193623
Fondation Leenaards / 2016 Fellowship for Academic Promotion in Clinical Medicine
Other / European Cooperation in Science and Technology (COST) Action CA16112 (NutRedOx)
Other / Exchange in Endocrinology Expertise (3E) Fellowship
Create date
28/11/2020 9:58
Last modification date
19/08/2022 6:14
Usage data